DiaMedica Therapeutics (DMAC)
Market Price (6/27/2026): $6.51 | Market Cap: $350.2 MilSector: Health Care | Industry: Biotechnology
DiaMedica Therapeutics (DMAC)
Market Price (6/27/2026): $6.51Market Cap: $350.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 28.22 Key risksDMAC key risks include [1] its overwhelming dependence on the clinical trial success of its sole lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -37 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 28.22 |
| Key risksDMAC key risks include [1] its overwhelming dependence on the clinical trial success of its sole lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/23/2026
DiaMedica Therapeutics (DMAC) stock has lost about 20% since 2/28/2026 because of the following key factors:
1. DiaMedica Therapeutics reported an increased net loss and missed EPS estimates for fiscal Q1 2026, which ended on March 31, 2026. The company posted a net loss of $10.0 million, a rise from $7.7 million in fiscal Q1 2025. Additionally, the reported EPS of -$0.19 fell short of the consensus estimate of -$0.17 by $0.02.
2. The company experienced a notable increase in Research and Development (R&D) expenses. R&D expenditures climbed to $8.0 million in fiscal Q1 2026, up from $5.7 million in fiscal Q1 2025, contributing to the larger net loss and higher operational costs as clinical programs progress.
Show more
DiaMedica Therapeutics (DMAC) stock has lost about 20% since 2/28/2026 because of the following key factors:
1. DiaMedica Therapeutics reported an increased net loss and missed EPS estimates for fiscal Q1 2026, which ended on March 31, 2026. The company posted a net loss of $10.0 million, a rise from $7.7 million in fiscal Q1 2025. Additionally, the reported EPS of -$0.19 fell short of the consensus estimate of -$0.17 by $0.02.
2. The company experienced a notable increase in Research and Development (R&D) expenses. R&D expenditures climbed to $8.0 million in fiscal Q1 2026, up from $5.7 million in fiscal Q1 2025, contributing to the larger net loss and higher operational costs as clinical programs progress.
Show more
Updated on 6/23/2026
DiaMedica Therapeutics (DMAC) stock has lost about 20% since 2/28/2026 because of the following key factors:
1. DiaMedica Therapeutics reported an increased net loss and missed EPS estimates for fiscal Q1 2026, which ended on March 31, 2026. The company posted a net loss of $10.0 million, a rise from $7.7 million in fiscal Q1 2025. Additionally, the reported EPS of -$0.19 fell short of the consensus estimate of -$0.17 by $0.02.
2. The company experienced a notable increase in Research and Development (R&D) expenses. R&D expenditures climbed to $8.0 million in fiscal Q1 2026, up from $5.7 million in fiscal Q1 2025, contributing to the larger net loss and higher operational costs as clinical programs progress.
3. DiaMedica Therapeutics continued to experience cash burn, reducing its cash reserves. Cash and short-term investments decreased from $59.9 million at the end of fiscal Q4 2025 to $51.3 million by the close of fiscal Q1 2026. While the company anticipates a cash runway through 2027, this consistent reduction in cash reflects ongoing development costs without immediate revenue generation.
4. The absence of immediate, definitive positive clinical trial catalysts likely contributed to investor caution. While DiaMedica announced that its ReMEDy2 Phase 2/3 Acute Ischemic Stroke trial surpassed 75% enrollment, triggering an interim analysis, this analysis is not expected until fiscal Q4 2026. Additionally, the initiation of a Phase 2 trial for DM199 in Fetal Growth Restriction on June 23, 2026, and updates on the preeclampsia trial were ongoing developments rather than conclusive positive data readouts.
5. Regulatory feedback from the FDA regarding nonclinical studies for DM199 in preeclampsia introduced ongoing requirements. On June 16, 2026, the FDA provided feedback indicating that prior nonclinical reproductive toxicity studies on rats might suffice for a U.S. Investigational New Drug (IND) application. However, this was contingent on demonstrating adequate DM199 exposure and enzymatic activity, and showing significant pharmacologic effects in rats, highlighting continued regulatory milestones rather than a clear path forward.
Show less
DiaMedica Therapeutics (DMAC) stock has lost about 20% since 2/28/2026 because of the following key factors:
1. DiaMedica Therapeutics reported an increased net loss and missed EPS estimates for fiscal Q1 2026, which ended on March 31, 2026. The company posted a net loss of $10.0 million, a rise from $7.7 million in fiscal Q1 2025. Additionally, the reported EPS of -$0.19 fell short of the consensus estimate of -$0.17 by $0.02.
2. The company experienced a notable increase in Research and Development (R&D) expenses. R&D expenditures climbed to $8.0 million in fiscal Q1 2026, up from $5.7 million in fiscal Q1 2025, contributing to the larger net loss and higher operational costs as clinical programs progress.
3. DiaMedica Therapeutics continued to experience cash burn, reducing its cash reserves. Cash and short-term investments decreased from $59.9 million at the end of fiscal Q4 2025 to $51.3 million by the close of fiscal Q1 2026. While the company anticipates a cash runway through 2027, this consistent reduction in cash reflects ongoing development costs without immediate revenue generation.
4. The absence of immediate, definitive positive clinical trial catalysts likely contributed to investor caution. While DiaMedica announced that its ReMEDy2 Phase 2/3 Acute Ischemic Stroke trial surpassed 75% enrollment, triggering an interim analysis, this analysis is not expected until fiscal Q4 2026. Additionally, the initiation of a Phase 2 trial for DM199 in Fetal Growth Restriction on June 23, 2026, and updates on the preeclampsia trial were ongoing developments rather than conclusive positive data readouts.
5. Regulatory feedback from the FDA regarding nonclinical studies for DM199 in preeclampsia introduced ongoing requirements. On June 16, 2026, the FDA provided feedback indicating that prior nonclinical reproductive toxicity studies on rats might suffice for a U.S. Investigational New Drug (IND) application. However, this was contingent on demonstrating adequate DM199 exposure and enzymatic activity, and showing significant pharmacologic effects in rats, highlighting continued regulatory milestones rather than a clear path forward.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -17.6% change in DMAC stock from 2/28/2026 to 6/26/2026 was primarily driven by a -7.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.95 | 6.55 | -17.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 50 | 54 | -7.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/26/2026| Return | Correlation | |
|---|---|---|
| DMAC | -17.6% | |
| Market (SPY) | 6.6% | 29.8% |
| Sector (XLV) | 0.5% | 23.1% |
Fundamental Drivers
The -24.1% change in DMAC stock from 11/30/2025 to 6/26/2026 was primarily driven by a -7.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.63 | 6.55 | -24.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 50 | 54 | -7.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/26/2026| Return | Correlation | |
|---|---|---|
| DMAC | -24.1% | |
| Market (SPY) | 7.3% | 32.3% |
| Sector (XLV) | 2.6% | 16.8% |
Fundamental Drivers
The 59.4% change in DMAC stock from 5/31/2025 to 6/26/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312025 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.11 | 6.55 | 59.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 43 | 54 | -20.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/26/2026| Return | Correlation | |
|---|---|---|
| DMAC | 59.4% | |
| Market (SPY) | 25.1% | 31.0% |
| Sector (XLV) | 23.0% | 19.5% |
Fundamental Drivers
The 139.9% change in DMAC stock from 5/31/2023 to 6/26/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312023 | 6262026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.73 | 6.55 | 139.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 26 | 54 | -50.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/26/2026| Return | Correlation | |
|---|---|---|
| DMAC | 139.9% | |
| Market (SPY) | 81.3% | 24.5% |
| Sector (XLV) | 31.9% | 17.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DMAC Return | -63% | -58% | 80% | 91% | 47% | -23% | -39% |
| Peers Return | -18% | 18% | 36% | 16% | 33% | 9% | 123% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| DMAC Win Rate | 25% | 42% | 50% | 67% | 67% | 33% | |
| Peers Win Rate | 40% | 43% | 48% | 45% | 58% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| DMAC Max Drawdown | -70% | -71% | -53% | -41% | -49% | -39% | |
| Peers Max Drawdown | -54% | -45% | -44% | -46% | -40% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BIIB, AMGN, TVTX, AKBA, ARDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
| Event | DMAC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -49.2% | -18.8% |
| % Gain to Breakeven | 96.7% | 23.1% |
| Time to Breakeven | 153 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -36.7% | -9.5% |
| % Gain to Breakeven | 58.0% | 10.5% |
| Time to Breakeven | 206 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.8% | -24.5% |
| % Gain to Breakeven | 231.6% | 32.4% |
| Time to Breakeven | 258 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -58.2% | -33.7% |
| % Gain to Breakeven | 139.1% | 50.9% |
| Time to Breakeven | 85 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -49.0% | -19.2% |
| % Gain to Breakeven | 96.2% | 23.8% |
| Time to Breakeven | 425 days | 105 days |
| 2013 Taper Tantrum | ||
| % Loss | -14.4% | -0.2% |
| % Gain to Breakeven | 16.8% | 0.2% |
| Time to Breakeven | 1784 days | 1 days |
In The Past
DiaMedica Therapeutics's stock fell -49.2% during the 2025 US Tariff Shock. Such a loss loss requires a 96.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | DMAC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -49.2% | -18.8% |
| % Gain to Breakeven | 96.7% | 23.1% |
| Time to Breakeven | 153 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -36.7% | -9.5% |
| % Gain to Breakeven | 58.0% | 10.5% |
| Time to Breakeven | 206 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.8% | -24.5% |
| % Gain to Breakeven | 231.6% | 32.4% |
| Time to Breakeven | 258 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -58.2% | -33.7% |
| % Gain to Breakeven | 139.1% | 50.9% |
| Time to Breakeven | 85 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -49.0% | -19.2% |
| % Gain to Breakeven | 96.2% | 23.8% |
| Time to Breakeven | 425 days | 105 days |
In The Past
DiaMedica Therapeutics's stock fell -49.2% during the 2025 US Tariff Shock. Such a loss loss requires a 96.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel treatments for patients afflicted with neurological and kidney diseases. Based in Minneapolis, Minnesota, the company focuses its research and development efforts on conditions with significant unmet medical needs.
The company's primary asset is DM199, a recombinant human tissue kallikrein-1 protein, which is currently in advanced clinical development. DM199 is being evaluated in a Phase 2 trial (REDUX) for individuals with moderate to severe chronic kidney disease stemming from Type I or Type II diabetes, addressing a critical need in nephrology. Concurrently, it's also in Phase 2/3 trials (REMEDY2) for the treatment of acute ischemic stroke, targeting a significant neurological condition. Beyond DM199, DiaMedica is also developing DM300, a preclinical-stage candidate aimed at inflammatory diseases, indicating a broader future interest in the immunology market.
AI Analysis | Feedback
Here are a few analogies for DiaMedica Therapeutics (DMAC):
- It's like an early-stage Biogen, focused on developing innovative drugs for neurological and kidney diseases.
- Think of it as a clinical-stage Vertex Pharmaceuticals, striving to bring its first breakthrough therapies for kidney and neurological conditions to market.
AI Analysis | Feedback
- DM199: A recombinant human tissue kallikrein-1 protein in clinical trials for chronic kidney disease and acute ischemic stroke.
- DM300: A drug candidate in the pre-clinical stage for the treatment of inflammatory diseases.
AI Analysis | Feedback
As a clinical-stage biopharmaceutical company, DiaMedica Therapeutics Inc. (DMAC) is primarily focused on the research and development of drug candidates, conducting clinical trials, and seeking regulatory approvals. The company has not yet commercialized any products. Therefore, DiaMedica Therapeutics does not currently have major customers in the traditional sense of companies or individuals purchasing its products.
AI Analysis | Feedback
The major suppliers for DiaMedica Therapeutics are:
- Wuxi Biologics Holdings Inc. (Symbol: 2269.HK)
- Novotech (Australia) Pty Limited
AI Analysis | Feedback
Rick Pauls - President and Chief Executive Officer
Mr. Pauls was appointed President and Chief Executive Officer of DiaMedica Therapeutics Inc. in 2009 and has served as a director since 2005. He also served as Chairman of the Board from 2008 to 2014. Before joining DiaMedica, Mr. Pauls co-founded and served as Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from 2002 to 2010. He was also an analyst for Centara Corporation, another early-stage venture capital fund, from 2000 to 2002.
Scott Kellen - Chief Financial Officer and Secretary
Mr. Kellen joined DiaMedica Therapeutics in January 2018 as Vice President of Finance and was appointed Chief Financial Officer and Secretary in April 2018. Prior to DiaMedica, Mr. Kellen was Vice President and Chief Financial Officer of Sun BioPharma, Inc., a publicly-traded clinical-stage drug development company, from 2015 to 2018. From 2010 to 2015, he served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly-traded medical device company, also becoming its Chief Operating Officer in 2012. Mr. Kellen has over 25 years of experience in the life sciences industry, focusing on publicly traded early-stage and growth companies.
Julie Krop, M.D. - Chief Medical Officer
Dr. Krop was appointed Chief Medical Officer effective August 2025. She brings over 20 years of experience as a strategic physician executive in both pre-commercial and commercial organizations across various therapeutic and orphan indications. Before DiaMedica, Dr. Krop served as CMO and Head of Development at PureTech Health. Previously, she was CMO at Freeline Therapeutics, where she contributed to a successful IPO and oversaw gene therapy programs. Dr. Krop also held the role of CMO and Executive Vice President at AMAG Pharmaceuticals, where she was involved in the approval of three drugs.
Ambarish Shah, Ph.D. - Chief Technology Officer
Dr. Shah was appointed Chief Technology Officer effective September 2023. He has more than 25 years of experience in advancing biopharmaceuticals from early development to commercialization. Before joining DiaMedica, Dr. Shah was Vice President and Head of Global Vaccines Development at CSL Seqirus, where he was responsible for end-to-end chemistry, manufacturing, and control (CMC) in vaccine development. Prior to that, he was Executive Director, Head of Drug Product Development at Bristol-Myers Squibb (formerly Celgene).
Dominic Cundari - Chief Commercial Officer
Mr. Cundari was appointed Chief Commercial Officer effective February 2022. He has over 30 years of pharmaceutical experience in various commercial roles within high-growth markets. Before joining DiaMedica, Mr. Cundari worked as an independent commercial strategy and development consultant for Genentech since 2009. From 1988 to 2009, he held various sales and marketing management positions at Genentech.
AI Analysis | Feedback
DiaMedica Therapeutics (DMAC), as a clinical-stage biopharmaceutical company, faces inherent and significant risks primarily centered on the successful development and commercialization of its drug candidates. The key risks to the business are:
1. Clinical Trial Risk
The most significant risk for DiaMedica Therapeutics is the uncertainty surrounding the outcome of its ongoing and future clinical trials for lead drug candidate DM199 (for chronic kidney disease, acute ischemic stroke, and preeclampsia) and pre-clinical stage DM300. The success of DiaMedica's business hinges entirely on these trials demonstrating efficacy and safety. There is a substantial risk of a sharp stock decline if DM199 clinical trials fail. Existing preclinical and earlier clinical data may not be predictive of the results of ongoing or later clinical trials, and unexpected adverse events or delays can significantly impact the company's prospects. For instance, the ReMEDy2 trial for acute ischemic stroke experienced a clinical hold due to transient acute hypotension, highlighting the potential for unforeseen challenges in the trial process. Safety concerns, including potential adverse events like angioedema and oral candidiasis, could also hinder patient acceptance and regulatory approval.2. Regulatory Approval Risk
Following successful clinical trials, DiaMedica Therapeutics must navigate complex and uncertain regulatory approval processes with health authorities such as the FDA and Health Canada. Even if clinical data is positive, there is no guarantee that regulatory bodies will grant approval for its drug candidates. Failure to reproduce positive outcomes in larger, more diverse populations during later-stage trials could lead to delays or limitations in regulatory approvals, which would consequently cap or delay potential revenue and earnings.3. Financing Risk / Cash Burn
As a company without revenue generation from approved products, DiaMedica Therapeutics relies heavily on its ability to raise sufficient capital to fund its extensive and costly research and development activities, particularly its clinical trials. The company faces continuous cash burn, necessitating future additional funding. While DiaMedica has reported cash, cash equivalents, and investments that are anticipated to provide a runway into the second half of 2027 (as of late 2025/early 2026 reports), delays in clinical timelines or the need for additional studies could require further capital, potentially leading to shareholder dilution. The cash burn rate increased by 43% in the last year, indicating that the actual cash runway could be shorter if this trend of increasing expenditure continues.AI Analysis | Feedback
null
AI Analysis | Feedback
DiaMedica Therapeutics (DMAC) is developing treatments for neurological and kidney diseases with its lead drug candidate, DM199, and is also developing DM300 for inflammatory diseases.
DM199 Addressable Markets
- Chronic Kidney Disease Caused by Type I or Type II Diabetes (Diabetic Nephropathy): The global diabetic kidney disease market was valued at approximately USD 3.03 billion in 2024 and is projected to reach USD 4.21 billion by 2031. The U.S. diabetic nephropathy market is estimated to reach USD 1.59 billion by 2032.
- Acute Ischemic Stroke: The global acute ischemic stroke therapeutics market size was valued at USD 9.13 billion in 2024 and is projected to grow to USD 19.35 billion by 2033.
DM300 Addressable Markets
- Inflammatory Diseases: The global inflammatory diseases biologics market size was approximately USD 99.06 billion in 2024 and is expected to reach USD 157.31 billion by 2033. North America holds a significant share of this market.
AI Analysis | Feedback
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company, anticipates its future revenue growth over the next 2-3 years to be primarily driven by the successful development and potential commercialization of its lead drug candidate, DM199. The key drivers include:
- Advancement and Potential Approval of DM199 for Acute Ischemic Stroke (AIS): DM199 is currently in Phase 2/3 REMEDY2 trials for the treatment of acute ischemic stroke. Analysts project significant revenue for DiaMedica Therapeutics in 2027 and 2028, with forecasts ranging up to $609 million and $2.3 billion, respectively, which is contingent on the successful commercialization of DM199 for this indication. An interim analysis for the ReMEDy2 stroke trial is anticipated in the second half of 2026.
- Advancement and Potential Approval of DM199 for Preeclampsia and Fetal Growth Restriction: DiaMedica Therapeutics is also progressing DM199 through Phase 2 trials for preeclampsia and fetal growth restriction. The company aims to complete the expansion cohort of its preeclampsia trial in the first half of 2026 and subsequently initiate a U.S. Phase 2 trial. Preeclampsia is identified as a critically underserved area with substantial unmet medical needs and a large commercial opportunity, positioning DM199 as a potential first-in-class treatment.
- Geographic Expansion and Market Penetration of DM199: The company's ReMEDy2 trial for acute ischemic stroke is undergoing global expansion, having secured regulatory clearance in the U.K. and with anticipated expansion into Europe. Broader geographical reach for DM199, following regulatory approvals, would contribute to a larger addressable market and subsequent revenue growth.
- Successful Achievement of Clinical Milestones and Regulatory Approvals for DM199: The realization of future revenue growth is fundamentally dependent on the successful completion of ongoing clinical trials for DM199 in both acute ischemic stroke and preeclampsia, followed by obtaining the necessary regulatory approvals. These milestones are critical precursors to any market entry and commercial sales.
AI Analysis | Feedback
Share Issuance
- DiaMedica Therapeutics closed a private placement of common shares in July 2025, resulting in net proceeds of approximately $29.9 million from the sale of about 8.6 million common shares at $3.50 per share.
- The company filed a Form S-8 registering 1,000,000 common shares for issuance under its 2021 Employment Inducement Incentive Plan, with the Board amending the plan in July 2025 to reserve an additional 1,000,000 shares for equity awards as inducement to employment.
- DiaMedica Therapeutics reported 52 million shares outstanding in Q3 2025, an increase of 0.8% from the prior quarter, indicating ongoing share issuance.
Inbound Investments
- In July 2025, DiaMedica Therapeutics received approximately $29.9 million in net proceeds from a private placement of common shares to accredited investors, which included approximately $16.8 million from certain non-management related parties.
- A significant shareholder, Jan Stahlberg, purchased 1,061,277 shares valued at $7,624,976 in DiaMedica Therapeutics in December 2025.
- Paragon Associates & Paragon Associates II Joint Venture increased its stake in DiaMedica by 34.6% in Q3, buying 225,000 shares to hold 875,000 shares, valued at approximately $6.01 million.
Capital Expenditures
- DiaMedica Therapeutics reported capital expenditures of $16K in Q3 2025, primarily for funding long-term assets and infrastructure.
- For the last 12 months, capital expenditures were reported at -$41,000.
- Annual capital expenditures were consistently low, reported as $0.0 million in 2020, 2021, 2023, and 2024, and -$0.1 million in 2022.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| DiaMedica Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 32.70 |
| Mkt Cap | 3.4 |
| Rev LTM | 482 |
| Op Inc LTM | -16 |
| FCF LTM | 12 |
| FCF 3Y Avg | -14 |
| CFO LTM | 50 |
| CFO 3Y Avg | -12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 18.2% |
| Rev Chg 3Y Avg | 12.5% |
| Rev Chg Q | 5.8% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 23.8% |
| Op Inc Chg 3Y Avg | 11.3% |
| Op Mgn LTM | 2.3% |
| Op Mgn 3Y Avg | -9.5% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 26.0% |
| CFO/Rev 3Y Avg | -2.1% |
| FCF/Rev LTM | 22.5% |
| FCF/Rev 3Y Avg | -3.3% |
Segment Financials
Revenue by Segment| $ Mil | 2018 |
|---|---|
| Development of its drug product candidate DM199 for the treatment of severe ischemic disease | 0 |
| Total | 0 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Development of its drug product candidate DM199 for the treatment of severe ischemic disease | -34 | -27 |
| Total | -34 | -27 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Development of its drug product candidate DM199 for the treatment of severe ischemic disease | -33 | -24 |
| Total | -33 | -24 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Development of its drug product candidate DM199 for the treatment of severe ischemic disease | 54 | 34 | 46 | 28 | 9 |
| Total | 54 | 34 | 46 | 28 | 9 |
Price Behavior
Price Behavior
| Market Price | $6.55 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 06/01/2009 | |
| Distance from 52W High | -30.2% | |
| 50 Days | 200 Days | |
| DMA Price | $6.06 | $7.16 |
| DMA Trend | indeterminate | down |
| Distance from DMA | 8.1% | -8.6% |
| 3M | 1YR | |
| Volatility | 49.0% | 66.7% |
| Downside Capture | 251.40 | 215.72 |
| Upside Capture | 116.39 | 234.88 |
| Correlation (SPY) | 28.6% | 32.3% |
DMAC Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.43 | 1.86 | 1.35 | 1.59 | 1.89 | 1.17 |
| Up Beta | 2.42 | -0.46 | 0.25 | 0.95 | 1.63 | 1.13 |
| Down Beta | 0.38 | -0.47 | -0.69 | -0.65 | 0.87 | 0.69 |
| Up Capture | 266% | 148% | 135% | 224% | 416% | 328% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 11 | 21 | 28 | 55 | 119 | 356 |
| Down Capture | 683% | 736% | 299% | 249% | 176% | 109% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 9 | 20 | 35 | 68 | 127 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMAC | |
|---|---|---|---|---|
| DMAC | 63.4% | 66.8% | 1.00 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 19.7% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 31.6% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 12.3% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -11.6% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 20.7% |
| Bitcoin (BTCUSD) | -44.7% | 42.5% | -1.27 | 21.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMAC | |
|---|---|---|---|---|
| DMAC | -4.2% | 76.8% | 0.28 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 13.2% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 19.1% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 5.5% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | 1.3% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 15.8% |
| Bitcoin (BTCUSD) | 10.7% | 54.0% | 0.39 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with DMAC | |
|---|---|---|---|---|
| DMAC | 7.5% | 82.1% | 0.49 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 15.0% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 19.7% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | 3.4% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 7.9% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 17.0% |
| Bitcoin (BTCUSD) | 54.6% | 66.4% | 0.95 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 0.2% | -4.0% | -13.5% |
| 11/12/2025 | -14.1% | 15.7% | 37.4% |
| 8/12/2025 | 14.9% | 10.5% | 39.5% |
| 5/13/2025 | 0.5% | 3.9% | -2.0% |
| 3/17/2025 | -13.0% | -17.4% | -41.4% |
| 11/13/2024 | -3.3% | -5.6% | 26.3% |
| 8/7/2024 | 3.1% | 7.1% | 24.0% |
| 5/8/2024 | -6.3% | -13.3% | -26.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 12 | 12 |
| # Negative | 13 | 11 | 11 |
| Median Positive | 3.3% | 8.9% | 22.5% |
| Median Negative | -5.0% | -6.9% | -13.5% |
| Max Positive | 14.9% | 40.8% | 59.0% |
| Max Negative | -14.1% | -28.4% | -41.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | 0.2% | -4.0% | -13.5% |
| 11/12/2025 | -14.1% | 15.7% | 37.4% |
| 8/12/2025 | 14.9% | 10.5% | 39.5% |
| 5/13/2025 | 0.5% | 3.9% | -2.0% |
| 3/17/2025 | -13.0% | -17.4% | -41.4% |
| 11/13/2024 | -3.3% | -5.6% | 26.3% |
| 8/7/2024 | 3.1% | 7.1% | 24.0% |
| 5/8/2024 | -6.3% | -13.3% | -26.2% |
| 3/19/2024 | -1.8% | -3.5% | -11.7% |
| 11/13/2023 | 6.8% | 3.4% | 13.7% |
| 8/14/2023 | 4.4% | 2.8% | 14.1% |
| 5/15/2023 | -10.8% | 40.8% | 59.0% |
| 3/28/2023 | -3.3% | 7.2% | 4.6% |
| 11/9/2022 | -1.6% | -1.6% | 16.3% |
| 8/10/2022 | 9.8% | 5.8% | -12.1% |
| 5/4/2022 | 2.8% | -6.9% | -4.0% |
| 3/14/2022 | -0.4% | 21.6% | -2.2% |
| 11/10/2021 | 1.6% | -13.9% | -14.3% |
| 8/11/2021 | -5.0% | 15.7% | 21.0% |
| 5/5/2021 | -9.2% | -28.4% | -21.5% |
| 3/10/2021 | 3.5% | 14.5% | 12.5% |
| 11/4/2020 | -5.9% | -7.9% | 24.2% |
| 8/11/2020 | -1.9% | -4.6% | -24.6% |
| SUMMARY STATS | |||
| # Positive | 10 | 12 | 12 |
| # Negative | 13 | 11 | 11 |
| Median Positive | 3.3% | 8.9% | 22.5% |
| Median Negative | -5.0% | -6.9% | -13.5% |
| Max Positive | 14.9% | 40.8% | 59.0% |
| Max Negative | -14.1% | -28.4% | -41.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/19/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/19/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/28/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 03/14/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/05/2021 | 10-Q |
| 12/31/2020 | 03/10/2021 | 10-K |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/11/2020 | 10-Q |
| 03/31/2020 | 05/13/2020 | 10-Q |
| 12/31/2019 | 03/23/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
| 06/30/2019 | 08/13/2019 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,027 | -0.2% | Lowered | Guidance: 2,028 for 2027 | |||
Prior: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | 2,028 | ||||||
Insider Activity
Updated 6/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 8.57 | 73,099 | 626,817 | 75,679,855 | Form | |
| 2 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.89 | 40,253 | 317,721 | 69,085,486 | Form | |
| 3 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.41 | 208,872 | 1,547,574 | 64,551,840 | Form | |
| 4 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.41 | 128,426 | 951,213 | 62,983,007 | Form | |
| 5 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.21 | 240,352 | 1,732,361 | 60,364,313 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 8.57 | 73,099 | 626,817 | 75,679,855 | Form | |
| 2 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.89 | 40,253 | 317,721 | 69,085,486 | Form | |
| 3 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.41 | 208,872 | 1,547,574 | 64,551,840 | Form | |
| 4 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.41 | 128,426 | 951,213 | 62,983,007 | Form | |
| 5 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 7.21 | 240,352 | 1,732,361 | 60,364,313 | Form | |
| 6 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 6.75 | 182,882 | 1,234,618 | 54,916,816 | Form | |
| 7 | Stahlberg, Jan | See Footnote | Buy | 12082025 | 6.52 | 187,393 | 1,221,165 | 51,819,078 | Form | |
| 8 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 6.00 | 50,772 | 304,632 | 46,586,790 | Form | |
| 9 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 6.00 | 59,648 | 357,888 | 46,282,158 | Form | |
| 10 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 6.00 | 338,265 | 2,029,252 | 45,916,616 | Form | |
| 11 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 5.96 | 59,788 | 356,576 | 43,631,312 | Form | |
| 12 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 5.96 | 48,172 | 287,028 | 43,234,103 | Form | |
| 13 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 5.86 | 71,107 | 416,495 | 42,218,364 | Form | |
| 14 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 6.00 | 8,233 | 49,398 | 42,820,278 | Form | |
| 15 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 5.99 | 70,414 | 421,921 | 42,713,852 | Form | |
| 16 | Stahlberg, Jan | See Footnote | Buy | 9042025 | 5.91 | 293,601 | 1,734,918 | 41,706,818 | Form | |
| 17 | Stahlberg, Jan | See Footnote 1 | Buy | 7252025 | 3.50 | 1,542,857 | 5,400,000 | 23,675,628 | Form | |
| 18 | Von, Koch Thomas | See Footnote 1 | Buy | 7252025 | 3.50 | 2,857,142 | 9,999,997 | 29,342,520 | Form | |
| 19 | Jacinto, Richard II | Roth IRA | Buy | 7252025 | 3.50 | 400,000 | 1,400,000 | 17,355,880 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/26/2026